Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Oral Semaglutide Formulations in Healthy Participants
NCT05227196Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state and Maximum semaglutide plasma concentration at steady state. Started Feb 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05227196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227196.